Patents by Inventor Lykke Pedersen

Lykke Pedersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240085402
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: October 20, 2023
    Publication date: March 14, 2024
    Inventors: Veronica COSTA, Maj HEDTJÄRN, Marius HOENER, Ravi JAGASIA, Mads Aaboe JENSEN, Christoph PATSCH, Lykke PEDERSEN, Søren Vestergaard RASMUSSEN
  • Patent number: 11898145
    Abstract: The present disclosure provides antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1). The disclosure also provides, enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection. Also disclosed are pharmaceutical compositions and their use.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: February 13, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Erik Funder, Natascha Hruschka, Susanne Kammler, Erich Koller, Brian Leonard, Souphalone Luangsay, Susanne Mohr, Tobias Nilsson, Søren Ottosen, Lykke Pedersen, Søren V. Rasmussen, Steffen Schmidt, Sabine Sewing, Daniel Turley, Johanna Marie Walther
  • Patent number: 11852627
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: December 26, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Publication number: 20230331837
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Application
    Filed: October 7, 2022
    Publication date: October 19, 2023
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Soren OTTOSEN, Souphalone LUANGSAY
  • Publication number: 20230296587
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD1091B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: February 22, 2023
    Publication date: September 21, 2023
    Inventors: Veronica COSTA, Maj HEDTJÄRN, Marius HOENER, Ravi JAGASIA, Mads Aaboe JENSEN, Christoph PATSCH, Lykke PEDERSEN, Søren Vestergaard RASMUSSEN
  • Patent number: 11732262
    Abstract: The present invention relates to a FUBP1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBP1 and capable of reducing a FUBP1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: August 22, 2023
    Inventors: Souphalone Luangsay, Barbara Testoni, Fabien Zoulim, Soren Ottosen, Lykke Pedersen
  • Publication number: 20230257748
    Abstract: The present invention relates to an A1CF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of A1CF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to A1CF and capable of reducing the level of an A1CF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
    Type: Application
    Filed: February 17, 2023
    Publication date: August 17, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Dennis JUL HANSEN, Souphalone LUANGSAY, Alan James MUELLER-BRECKENRIDGE, Lykke PEDERSEN, Johanna Marie POSE VICENTE
  • Publication number: 20230210887
    Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis virus (HBV) infection, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a BV infection. The invention also provides for inhibitors of PAPD5 or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.
    Type: Application
    Filed: December 22, 2022
    Publication date: July 6, 2023
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Hassan JAVANBAKHT, Soren OTTOSEN, Lykke PEDERSEN, Henrik MUELLER
  • Publication number: 20230212572
    Abstract: The present invention relates to a polynucleotide that comprises at least one phosphorothioate internucleoside linkage and at least one guanosine analogue comprising a guanine nucleobase analogue selected from the group consisting of: formula (I) and formula (II). Polynucleotides comprising such guanosine analogues show a relative reduced neurotoxicity compared to polynucleotides with natural guanosine.
    Type: Application
    Filed: June 8, 2021
    Publication date: July 6, 2023
    Inventors: Nanna Albaek, Peter Hagedorn, Mette Ladefoged, Lykke Pedersen, Jacob Ravn
  • Publication number: 20230193263
    Abstract: The present invention relates to a SBDS inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SBDS inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SBDS and capable of reducing the level of a SBDS mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
    Type: Application
    Filed: June 21, 2022
    Publication date: June 22, 2023
    Inventors: Souphalone Luangsay, Alan James Mueller-Breckenridge, Lykke Pedersen, Johanna Marie Walther
  • Publication number: 20230183692
    Abstract: The present invention relates to a SEPT9 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SEPT9 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SEPT9 and capable of reducing the level of a SEPT9 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
    Type: Application
    Filed: June 21, 2022
    Publication date: June 15, 2023
    Inventors: Lykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge
  • Publication number: 20230118138
    Abstract: The present invention relates to a SCAMP3 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SCAMP3 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SCAMP3 and capable of reducing the level of a SCAMP3 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
    Type: Application
    Filed: June 21, 2022
    Publication date: April 20, 2023
    Inventors: Lykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge
  • Publication number: 20230122751
    Abstract: The present invention relates to a COPS3 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of COPS3 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to COPS3 and capable of reducing the level of a COPS3 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
    Type: Application
    Filed: June 21, 2022
    Publication date: April 20, 2023
    Inventors: Lykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge
  • Publication number: 20230120063
    Abstract: The present invention relates to a SARAF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SARAF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SARAF and capable of reducing the level of a SARAF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
    Type: Application
    Filed: June 21, 2022
    Publication date: April 20, 2023
    Inventors: Lykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge
  • Publication number: 20230113497
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: July 19, 2022
    Publication date: April 13, 2023
    Applicant: HOFFMAN-LA ROCHE INC.
    Inventors: Susanne KAMMLER, Anais LOPEZ, Henrik MUELLER, Soren OTTOSEN, Lykke PEDERSEN
  • Publication number: 20230060373
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to ATXN3 pre-mRNA sequences, which are capable of inhibiting the expression of ATXN3 protein. Inhibition of ATXN3 expression is beneficial for the treatment of spinocerebellar ataxia.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 2, 2023
    Inventors: Heidi Rye Hudlebusch, Alexander Herbert Stephan, Lykke Pedersen, Christoffer Sondergaard, Erik Funder
  • Publication number: 20230054720
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to ATXN3 pre-mRNA sequences, which are capable of inhibiting the expression of ATXN3 protein.
    Type: Application
    Filed: December 2, 2021
    Publication date: February 23, 2023
    Inventors: Heidi Rye Hudlebusch, Lykke Pedersen, Erik Funder, Lukasz Kielpinski, Christoffer Sondergaard, Alexander Herbert Stephan, Mads Manso
  • Patent number: 11542501
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to ATXN3 pre-mRNA sequences, which are capable of inhibiting the expression of ATXN3 protein. Inhibition of ATXN3 expression is beneficial for the treatment of spinocerebellar ataxia.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: January 3, 2023
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Marianne Ravn Møller, Heidi Rye Hudlebusch, Lykke Pedersen, Erik Daa Funder, Christoffer Sondergaard, Jette Dam Hedegaard, Alexander Herbert Stephan, Peter Hagedorn
  • Patent number: 11534452
    Abstract: A method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection is provided, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. Inhibitors of PAPD5 or PAPD7 are provided for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: December 27, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Hassan Javanbakht, Søren Ottosen, Lykke Pedersen, Henrik Mueller
  • Patent number: 11484546
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: November 1, 2022
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen